Immune Design (Immune Design) Dividends per Share : $0.00 (TTM As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Immune Design Dividends per Share?

Immune Design's dividends per share for the three months ended in Dec. 2018 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2018 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2018 was 0.00. As of today, Immune Design's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Immune Design Dividends per Share Historical Data

The historical data trend for Immune Design's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Dividends per Share Chart

Immune Design Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dividends per Share

Get a 7-Day Free Trial

Immune Design Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immune Design's Dividends per Share

For the Biotechnology subindustry, Immune Design's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immune Design's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Immune Design's Dividend Yield % falls into.

Immune Design Dividends per Share Calculation

Dividends paid to per common share.

Immune Design (NAS:IMDZ) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Immune Design's Dividend Payout Ratio for the quarter that ended in Dec. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2018 )	/	EPS without NRI (Q: Dec. 2018 )
	=	0	/	-0.57
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Immune Design Dividends per Share Related Terms

Thank you for viewing the detailed overview of Immune Design's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immune Design (Immune Design) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102

Website

http://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Executives

William R Ringo	director
David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya	director, officer: President and CEO	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005